SGLT2 expression in human vasculature and heart correlates with low-grade inflammation and causes eNOS-NO/ROS imbalance.

Date publication

décembre 2024

Journal

Cardiovascular research

Auteurs

Membres identifiés du Cancéropôle Est :
Pr MEYER Nicolas , Pr SCHINI-KERTH Valérie , Dr AUGER Cyril

Tous les auteurs :
Mroueh A, Algara-Suarez P, Fakih W, Gong DS, Matsushita K, Park SH, Amissi S, Auger C, Kauffenstein G, Meyer N, Ohlmann P, Jesel L, Pieper MP, Marchandot B, Morel O, Mazzucotelli JP, Schini-Kerth VB

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39739876

Résumé

Sodium-glucose co-transporter 2 inhibitors (SGLT2i) show a cardioprotective effect in heart failure and myocardial infarction, pathologies often associated with low-grade inflammation. This cross-sectional study aims to investigate whether low-grade inflammation regulates SGLT2 expression and function in human vasculature, heart, and endothelial cells (ECs).

Mots clés

Cardiovascular disease, Endothelial dysfunction, Local angiotensin system, Oxidative stress, Pro-inflammatory cytokines, SGLT2

Référence

Cardiovasc Res. 2024 12 31;: